Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 2 Prevalence of anti-CarP, ACPA and RF in RA patients, disease controls and healthy subjects

From: Erratum to: Prevalence, sensitivity and specificity of antibodies against carbamylated proteins in a monocentric cohort of patients with rheumatoid arthritis and other autoimmune rheumatic diseases

Disease
(No of patients)
Anti-CarP positive n, (%) ACPA positive n, (%) RF positive n, (%)
RA (309) 117 (37.9) 190 (61.4) 202 (65.3)
NHS (98) 2 (2.04) 1 (1.02) 3 (3.06)
SLE (83) 14 (16.8) 15 (18.07) 19 (22.8)
SS (45) 14 (31.1) 11 (24.4) 23 (51.1)
SSc (51) 3 (5.8) 1 (1.9) 18 (35.2)
OP (21) 2 (9.5) 2 (9.5) 4 (19.04)
  1. Anti-CarP anti-carbamylated proteins antibodies, ACPA anti-citrullinated peptides antibodies, RF rheumatoid factor, RA Rheumatoid Arthritis, NHS Normal Healthy Subjects, SLE Systemic Lupus Erythematosus, SS Sjögren Syndrome, SSc Systemic Sclerosis, OP osteoporosis